1.A Case of Endometrioid Stromal Sarcoma of ovary.
Jeong Ho SONG ; Sung Chul JEON ; Ji Hoon KANG ; Kyun HAN ; Hyun Sung LEE ; In Soo HWANG ; Cheol Hong PARK ; Mi Sun LEE
Korean Journal of Obstetrics and Gynecology 2003;46(1):188-191
Endometrioid stromal sarcoma of ovary is so rare that it has been reported 45 cases in the world. Endometrioid stromal sarcoma of ovary is concomitant with endometriosis at 40%, with same tumor in uterus at 30%. The age of pateint is between 11 and 76, half of them are fifties and sixties. Most frequent presenting symptom is abdominal distension and abdominal pain. Surgery, chemotherapy, radiotherapy, progesterone was helpful, but any management do not result in conclusion because of rarity of cases. Clinical course is indolent because lesion is well-differentiated and grows slowly, so only cytoreductive surgery will be effective. Progesterone may be effective in residual or recurrent low-grade endometrioid stromal sarcoma of ovary. If endometriotic tissue is origin of tumor, estrogen play a role in malignant transformation. We had experienced a case of endometrioid stromal sarcoma of ovary of 42 years old woman. We managed by TAH and BSO, radiotherapy, progesterone therapy. Until now no recurrence was found for 15 months. So, we report this case with review of the literature.
Abdominal Pain
;
Adult
;
Drug Therapy
;
Endometriosis
;
Estrogens
;
Female
;
Humans
;
Ovary*
;
Progesterone
;
Radiotherapy
;
Recurrence
;
Sarcoma*
;
Uterus
2.Relief of Cancer Pain in Patients with Pancreatic Cancer
The Korean Journal of Gastroenterology 2019;74(2):81-86
Pancreatic cancer is a dismal disease with a poor prognosis and is one of the most painful malignancies. Therefore, adequate pain control is essential to improving the patient's quality of life. Pain in pancreatic cancer has complex pathophysiologic mechanisms and different characteristics. The choice of pain management modalities should be individualized depending on the pain characteristics using a multidisciplinary approach. The treatment options available include medical treatment, chemotherapy, celiac plexus/ganglion neurolysis, radiotherapy, and endoscopic technique. This review discusses the medical and interventional options, leading to optimal pain management in patients with pancreatic cancer.
Drug Therapy
;
Humans
;
Pain Management
;
Pancreatic Neoplasms
;
Prognosis
;
Quality of Life
;
Radiotherapy
3.Relief of Cancer Pain in Patients with Pancreatic Cancer
The Korean Journal of Gastroenterology 2019;74(2):81-86
Pancreatic cancer is a dismal disease with a poor prognosis and is one of the most painful malignancies. Therefore, adequate pain control is essential to improving the patient's quality of life. Pain in pancreatic cancer has complex pathophysiologic mechanisms and different characteristics. The choice of pain management modalities should be individualized depending on the pain characteristics using a multidisciplinary approach. The treatment options available include medical treatment, chemotherapy, celiac plexus/ganglion neurolysis, radiotherapy, and endoscopic technique. This review discusses the medical and interventional options, leading to optimal pain management in patients with pancreatic cancer.
Drug Therapy
;
Humans
;
Pain Management
;
Pancreatic Neoplasms
;
Prognosis
;
Quality of Life
;
Radiotherapy
4.The Palliative Radiation Therapy in Malignant Extra-Hepatic Biliary Obstruction.
Chul Seung KAY ; Hong Suk JANG ; Sung Hwan KIM ; Mi Ryeong RYU ; Yeon Shil KIM ; Su Mi CHUNG ; Sei Chul YOON
The Journal of the Korean Society for Therapeutic Radiology and Oncology 1999;17(3):209-216
PURPOSE: To evaluate the effectiveness of external radiation therapy and the prognostic factors, we retrospectively analyzed therapeutic results of malignant extrahepatic biliary obstruction (EHBO). METHODS AND MATERIALS: We analyzed the results of the external radiation therapy in 59 patients of inoperable malignant EHBO who had been treated with more than 10 Gy of external radiation therapy from April 1984 to December 1996. There were 21 stomach cancer (35.6%), 12 pancreas cancer (20.3%), 15 extrahepatic biliary cancer (18.6%) and 11 another cancer (18.6%). Their pathologies were confirmed in 31 patients (52.5%). They divided into 27 adenocarcinoma and 4 nonadenocarcinoma. Their chief complaints were jaundice in 47 patients (79.7%) and abdominal pain in 15 patients (49.2%). Twelve patients had slightly increased bilirubin level in liver function test without jaundice. We treated twenty four patients (40.6%) with percutaneous transhepatic biliary drainage (PTBD) and 32 patients (54%) with systemic chemotherapy (CT). We performed external radiation therapy (ERT) upto 10.8~55.8 Gy (median 37.8 Gy) with palliative aim. RESULTS: Overall median survival duration was 7.80+/-1.15 months. The response rates of jaundice were 81.8% in PTBD group and 66.7% in non-PTBD group without statistical significance. The improving rate of jaundice was not significantly different in decreased ratio of total bilirubin level. But abdominal pain was more decreased in CT group than non-CT group (P<0.05). The significant prognostic factors were high performance status (Karnofski Performance Status >70), total radiation dose more than 35 Gy and good response of pain after therapy. There were increased in bacterial cholagitis in PTBD group and gastrointestinal complications in CT group. CONCLUSION: External radiotheapy could improve jaundice and abdominal pain in malignant EHBO patients. Overall survival duration was prolonged in patients with higher performance status and patients who had been treated with more than 35 Gy of total radiation dose. In the future, we expect not only better palliative role but also the prolongation of survival of using the ERT combined with other treatment method. But to achieve certain conclusion, we need futher study consisted with many kinds of treatment methods including new technologies in RT.
Abdominal Pain
;
Adenocarcinoma
;
Bilirubin
;
Drainage
;
Drug Therapy
;
Humans
;
Jaundice
;
Liver Function Tests
;
Pancreatic Neoplasms
;
Pathology
;
Radiotherapy
;
Retrospective Studies
;
Stomach Neoplasms
5.A Case of Malignant Mixed Mullerian Tumor of the Fallopian Tube.
Da Jung CHUNG ; Jae Wook KIM ; Young Tae KIM ; Sung Hoon KIM
Korean Journal of Obstetrics and Gynecology 2004;47(4):804-808
Malignant mixed mullerain tumors (MMMT) are rare neoplasms of the female genital tract that histolotically consist of malignant epithelial and stromal components, arising in the endometirum, followed in decreasing order by the vagina, cervix, and ovary. Tubal origin is extremely rare and accounts for less than 4% of all MMMTs. Most of the patients present with nonspecific abdominal pain or abnormal vaginal bleeding. Nonspecific findings on imaging studies also make exact preoperative diagnosis very difficult, mostly mistaken as ovarian malignancies. The primary goal of treatment is removal of tumor mass by cytoreductive surgery. Postoperatively, chemotherapy or radiotherapy is added, but prognosis is very poor. The best form of postoperative adjuvant therapy is not yet established due to the rarity of this disease entity. We report a case of a malignant mixed mullerian tumor of the fallopian tube that we have experienced recently with a brief review of the literature.
Abdominal Pain
;
Cervix Uteri
;
Diagnosis
;
Drug Therapy
;
Fallopian Tubes*
;
Female
;
Humans
;
Ovary
;
Prognosis
;
Radiotherapy
;
Uterine Hemorrhage
;
Vagina
6.The Factors Influencing on Insertion of Double-J Catheter in Ureteral Obstruction due to Malignancy .
Yoon Bo LEE ; Jai Young YOON ; Tae Kon HWANG
Korean Journal of Urology 1998;39(1):82-86
PURPOSE: The aim of this presentation is to analyze the factors influencing on retrograde insertion of double-J catheter in urethral obstruction due to malignancy and to predict the possibility of stunting with double-J catheter. MATERIALS AND METHODS: A retrospective analysis of 43 patients who had underwent retrograde double-J catheter insertion for urethral obstruction secondary to pelvic malignancy, from January 1993 to April 1997, was performed to evaluate the success rates of double-J ureteral stenting according to the factors such as age, sex, presence or absence of flank pain, degree of hydronephrosis, renal function, stage of tumor, laterality of ureter, past history of radiotherapy, operation and chemotherapy. RESULTS: According to the degree of hydronephrosis, the success rate was 100, 73.7 and 50% in grade I II and III, respectively(p<0.05). According to the renal function, the success rate was 81.3% in the group with normal renal function and 45.5% in the group with abnormal venal function(p<0.05) According to the stage of disease, the success rate was 100, 70.7 and 58.3% in stage I, II and III, respectively. According to the absence or presence of flank pain, the success rate was 56.3% in the group with flank pain and 81.5% in the group without flank pain. According to the past history of radiotherapy, the success rate was 65.6% in the group treated with radiotherapy and 90.9% in the group not treated with radiotherapy. The age, sex, laterality of ureter, past history of operation and chemotherapy were not significantly correlated to the success rates. CONCLUSIONS: The factors influencing on double-J ureteral slanting were the degree of hydronephrosis, renal function, absence or presence of flank pain, stage of disease and past history of radiotherapy Further study will be needed to demonstrate the accurate timing of urethral stenting with doublets ureteral catheter.
Catheters*
;
Drug Therapy
;
Flank Pain
;
Humans
;
Hydronephrosis
;
Radiotherapy
;
Retrospective Studies
;
Stents
;
Ureter*
;
Ureteral Obstruction*
;
Urethral Obstruction
;
Urinary Catheters
7.Late-Developing Metastatic Malignant Melanoma in the Thoracic Spine Originating from Choroidal Melanoma.
Jun Kyu HWANG ; Kyung Hyun KIM ; Ji Sup KIM ; Sung Jun AHN ; Sung Uk KUH
Korean Journal of Spine 2017;14(2):53-56
A 54-year-old woman visited Gangnam Severance Hospital for left side flank pain. She had a history of total removal of malignant melanoma on the left eye ball 20 years prior. No evaluation had been performed since then. A paravertebral mass at thoracic ninth level (T9) was discovered on spinal magnetic resonance imaging, and pathology confirmed malignant melanoma. Following positron emission tomography-computed tomography, no other metastasis was discovered. After removal of the paravertebral mass, palliative chemotherapy (dacabarzine + tamoxifene) was administered in 3 cycles over 2 months. Radiotherapy with simultaneous integrated boost technique was performed at 4,350 cGy total over 15 days, 290 cGy per delivery, and was administered with the first cycle of palliative chemotherapy. Despite this treatment, multiple metastases developed throughout her body 7 months later, and the patient is continuing chemotherapy.
Choroid*
;
Drug Therapy
;
Electrons
;
Female
;
Flank Pain
;
Humans
;
Magnetic Resonance Imaging
;
Melanoma*
;
Middle Aged
;
Neoplasm Metastasis
;
Pathology
;
Radiotherapy
;
Spine*
8.Treatment of Mediastinal Growing Teratoma Syndrome: A case report.
Jong Ho CHO ; Ho Sung SON ; Won Min JO ; Byoung Ju MIN ; In Sung LEE ; Jae Seung SHIN
The Korean Journal of Thoracic and Cardiovascular Surgery 2005;38(10):729-732
A 15-year-old male was admitted with right-sided chest pain and cough for one month. On chest computed tomographic scan, a 10 x 15 x 16 cm-sized huge mediastinal mass was occupied in the right hemithorax. Radiologically, it seemed that the tumor was severely adhesive on the heart and the superior vena cava. Therefore we decided on chemotherapy and radiotherapy first instead of surgery. The tumor marker was nearly normalized afterwards, but the tumor size was seemed to be bigger on chest tomographic scan. This suggests the growing teratoma syndrome. After the successful resection, he showed symptomatic improvement and is being followed up without any symptoms in an out patient department up to now.
Adhesives
;
Adolescent
;
Chest Pain
;
Cough
;
Drug Therapy
;
Heart
;
Humans
;
Male
;
Mediastinal Neoplasms
;
Radiotherapy
;
Teratoma*
;
Thorax
;
Vena Cava, Superior
9.Neuropathic cancer pain: prevalence, pathophysiology, and management.
The Korean Journal of Internal Medicine 2018;33(6):1058-1069
Neuropathic cancer pain (NCP) is caused by nerve damage attributable to the cancer per se, and/or treatments including chemotherapy, radiotherapy, and surgery; the prevalence is reported to be as high as 40%. The etiologies of NCP include direct nerve invasion or nerve compression by the cancer, neural toxicity, chemotherapy, and radiotherapy. NCP is subdivided into plexopathy, radiculopathy, and peripheral neuropathies, among several other categories. The clinical characteristics of NCP differ from those of nociceptive pain in terms of both the hypersensitivity symptoms (burning, tingling, and an electrical sensation) and the hyposensitivity symptoms (numbness and muscle weakness). Recovery requires several months to years, even after recovery from injury. Management is complex; NCP does not usually respond to opioids, although treatments may feature both opioids and adjuvant drugs including antidepressants, anticonvulsants, and anti-arrhythmic agents, all of which improve the quality-of-life. This review addresses the pathophysiology, clinical characteristics and management of NCP, and factors rendering pain control difficult.
Analgesics, Opioid
;
Anticonvulsants
;
Antidepressive Agents
;
Drug Therapy
;
Hypersensitivity
;
Neuralgia
;
Nociceptive Pain
;
Peripheral Nervous System Diseases
;
Prevalence*
;
Radiculopathy
;
Radiotherapy
10.Interventional therapy for lung cancer patients with superior vena cava syndrome.
Jie LUO ; Bin CHEN ; Sen JIANG ; Song-wen ZHOU
Chinese Journal of Oncology 2013;35(8):627-631
OBJECTIVETo investigate the method, therapeutic effect and safety of interventional therapy for lung cancer patients with superior vena cava syndrome (SVCS).
METHODSFifty-two cases of lung cancer with SVCS who received interventional therapy in our hospital between Jan to Dec 2011 were included in this study. Of the 52 cases, 50 cases had successfully carried out superior vena cava stent implantation. The distal venous pressure was measured before and after angioplasty, and the results were assessed by Wilcoxon matched-pairs test. In addition, the 50 patients were followed up and the therapeutic effect and postoperative survival rate were evaluated.
RESULTSThe mean distal venous pressure in the 50 patients was significantly decreased from preoperative (28.2 ± 1.9)cm H2O to postoperative (8.7 ± 0.5)cm H2O (P = 0.0085). The efficacy of the treatment was as follows: complete remission (20/52, 38.5%), partial remission (28/52, 53.8%), ineffective 4 (4/52, 7.7%), and total effective rate 92.3%. The complications after angioplasty and stent implantation included chest pain (12 cases, 23.1%), hematoma at the puncture site (5 cases, 9.6%), and fever (2 cases, 3.8%). No serious complications such as massive hemorrhage, pulmonary embolism and stent migration into the cardiac atrium were observed. The rate of postoperative restenosis was low (2/52, 3.8%). For the SCLC group, the objective effective rate was 74.1% and 1-year survival rate was 21.0%. For the NSCLC group, the objective effective rate was 21.7% and 1-year survival rate was 35.0%.
CONCLUSIONSFor lung cancer patients with SVCS, interventional therapy may relief obstruction effectively, promote blood flow recovery, and relieve clinical symptoms. Interventional therapy with endovascular angioplasty and stenting may be highly recommended as the first choice for palliative treatment of SVCS. It is an effective initial palliative treatment. However, subsequent comprehensive anti-tumor treatment is necessary.
Adult ; Aged ; Angioplasty ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Blood Pressure ; Carcinoma, Non-Small-Cell Lung ; complications ; drug therapy ; radiotherapy ; Chest Pain ; etiology ; Female ; Follow-Up Studies ; Hematoma ; etiology ; Humans ; Lung Neoplasms ; complications ; drug therapy ; radiotherapy ; Male ; Middle Aged ; Radiotherapy, High-Energy ; Remission Induction ; Small Cell Lung Carcinoma ; complications ; drug therapy ; radiotherapy ; Stents ; Superior Vena Cava Syndrome ; complications ; therapy ; Survival Rate